Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer

Cancer Research

Volumn 71, Issue 20, 2011, Pages 6360-6370

  Pan, Deng ^a   Kocherginsky, Masha ^a   Conzen, Suzanne D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER MODEL; CANCER RELAPSE; CANCER STAGING; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR ALPHA GENE; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GLUCOCORTICOID RECEPTOR GENE; HUMAN; HUMAN CELL; PRECANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RELAPSE FREE SURVIVAL; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; UPREGULATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; RETROSPECTIVE STUDIES;

EID: 80054013673     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0362     Document Type: Article

References (58)

1. Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981;47:554-60. (Pubitemid 11174922)
2. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18. (Pubitemid 28536137)
3. Anan K, Mitsuyama S, Koga K, Tanabe R, Saimura M, Tanabe Y, et al. Disparities in the survival improvement of recurrent breast cancer. Breast Cancer 2010;17:48-55.
4. Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006;6:181-202.
5. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35. (Pubitemid 40128091)
6. Correa Geyer F, Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?Int J Surg Pathol 2009;17:285-302.
7. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
8. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009;20:1913-27.
9. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 2000;60:867-72. (Pubitemid 30129517)
10. Belova L, Delgado B, Kocherginsky M, Melhem A, Olopade OI, Conzen SD. Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat 2009;116:441-7.
11. Conzen SD. Minireview: nuclear receptors and breast cancer. Mol Endocrinol 2008;22:2215-28.
12. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001;276:16649-54.
13. Wu W, Pew T, Zou M, Pang D, Conzen SD. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005;280:4117-24. (Pubitemid 40288576)
14. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 2006;5:933-40.
15. Williams JB, Pang D, Delgado B, Kocherginsky M, Tretiakova M, Krausz T, et al. A model of gene-environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation. Cancer Prev Res (Phila) 2009;2:850-61.
16. Wu W, Zou M, Brickley DR, Pew T, Conzen SD. Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. Mol Endocrinol 2006;20:2304-14. (Pubitemid 44496403)
17. Itani OA, Liu KZ, Cornish KL, Campbell JR, Thomas CP. Glucocorticoids stimulate human sgk1 gene expression by activation of a GRE in its 5′-flanking region. Am J Physiol 2002;283:E971-9. (Pubitemid 35216955)
18. Burkhart BA, Kennett SB, Archer TK. Osmotic stress-dependent repression is mediated by histone H3 phosphorylation and chromatin structure. J Biol Chem 2007;282:4400-7. (Pubitemid 47100920)
19. Hebbar PB, Archer TK. Chromatin-dependent cooperativity between site-specific transcription factors in vivo. J Biol Chem 2007;282:8284-91. (Pubitemid 47093548)
20. Chen W, Rogatsky I, Garabedian MJ. MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol Endocrinol 2006;20:560-72. (Pubitemid 43291208)
21. Li H, Ruan J, Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 2008;18:1851-8.
22. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008;9:R137.
23. Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, et al. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res 2000;28:316-9. (Pubitemid 30047792)
24. Wingender E, Dietze P, Karas H, Knuppel R. TRANSFAC: a database on transcription factors and their DNA binding sites. Nucleic Acids Res 1996;24:238-41. (Pubitemid 26085775)
25. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
26. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (Oxford, England) 2004;20:307-15. (Pubitemid 38262761)
27. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
28. Brettschneider J, Collin F, Bolstad BM, Speed TP. Quality assessment for short oligonucleotide arrays. Technometrics 2007;50:241-64.
29. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007;53:1084-91. (Pubitemid 46867525)
30. Gentleman R, Carey V, Huber W, Hahne F. genefilter: methods for filtering genes from microarray experiments. R package.
31. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007;8:203-11.
32. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
33. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670-5.
34. Kent WJ. BLAT-the BLAST-like alignment tool. Genome Res 2002;12:656-64.
35. Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 2009;10:R130.
36. Therneau T, Lumley T. survival: Survival analysis, including penalised likelihood. R package. Available from: http://cran.r-project.org/web/packages/ survival/index.html.
37. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. (Pubitemid 32397092)
38. Schwender H. siggenes: Multiple testing using SAM and Efron's empirical Bayes approaches. R package. Available from: http://bioconductor.case.edu/ bioconductor/2.5/bioc/html/siggenes.html.
39. Luca F, Kashyap S, Southard C, Zou M, Witonsky D, Di Rienzo A, et al. Adaptive variation regulates the expression of the human SGK1 gene in response to stress. PLoS Genet 2009;5:e1000489.
40. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006;38:1289-97. (Pubitemid 44646291)
41. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR. Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 2007;3:e94.
42. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9. (Pubitemid 40260888)
43. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24. (Pubitemid 41112921)
44. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72. (Pubitemid 43264710)
45. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor- positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46. (Pubitemid 46640570)
46. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-14. (Pubitemid 46944903)
47. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008;9:239.
48. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-13.
49. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
50. Conde I, Paniagua R, Fraile B, Lucio J, Arenas MI. Glucocorticoid receptor changes its cellular location with breast cancer development. Histol Histopathol 2008;23:77-85.
51. Buxant F, Engohan-Aloghe C, Noel JC. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. Appl Immunohistochem Mol Morphol 2010;18:254-7.
52. Zhang Y, Leung DY, Nordeen SK, Goleva E. Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation. J Biol Chem 2009;284:24542-52.
53. Oakley RH, Cidlowski JA. Cellular processing of the glucocorticoid receptor gene and protein: New mechanisms for generating tissue specific actions of glucocorticoids. J Biol Chem 2011;286:3177-84.
54. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, et al. RBpathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2011;9:4153-63.
55. He J, Cheng Q, Xie W. Minireview: Nuclear receptor-controlled steroid hormone synthesis and metabolism. Mol Endocrinol 2010;24:11-21.
56. Zhou F, Bouillard B, Pharaboz-Joly MO, Andre J. Non-classical antiestrogenic actions of dexamethasone in variant MCF-7 human breast cancer cells in culture. Mol Cell Endocrinol 1989;66:189-97. (Pubitemid 19253389)
57. Gong H, Jarzynka MJ, Cole TJ, Lee JH, Wada T, Zhang B, et al. Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res 2008;68:7386-93.
58. Helming L, Gordon S. Molecular mediators of macrophage fusion. Trends Cell Biol 2009;19:514-22.